Capecitabine in Women With Operable Breast Cancer

A Phase II Study of Preoperative Capecitabine in Women With Operable Breast Cancer

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00148720

Enrollment

Registered

2005-09-08

Start date

2004-09-30

Completion date

Unknown

Last updated

2015-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Invasive Breast Carcinoma, Primary Invasive Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer

Keywords

Invasive Breast Cancer, Operable Breast Cancer, Capecitabine

Brief summary

The purpose of this study is to find out what effects (good and bad) taking capecitabine for 12 weeks before surgery will have on women with breast cancer.

Detailed description

* Prior to the start of treatment, patients will have a small metal clip inserted into the tumor bed to identify the tumor site to the surgeon. At that time, a needle biopsy of the breast tumor or a sentinel (underarm) lymph node biopsy will also be performed. * Patients will take capecitabine orally twice daily for 14 days. This treatment will repeat every 21 days (1 cycle). Patients will receive 4 cycles of this treatment. * A physical exam and blood work will be done every three weeks after starting therapy to monitor side effects. * After two weeks of capecitabine a biopsy from the tumor will be done to generate information about the characteristics of the tumor that may respond to capecitabine. * After completing 4 cycles (12 weeks) of capecitabine, patients will then undergo surgery to remove any remaining breast cancer (lumpectomy or mastectomy). Post-surgical treatment (radiation, chemotherapy, and hormonal therapy) is at the discretion of the patients physician.

Interventions

DRUGCapecitabine

Taken orally twice a day for 14 days and treatment will repeat every 21 days (1 cycle) for 4 cycles

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histological confirmation of primary invasive breast cancer * Stage I-III operable breast cancer. * Primary tumor must be greater than or equal to 2cm by radiographic imaging or palpitation * Women greater than 18 years of age * ECOG performance status 0-1 * WBC \> 4000/mm3 * Platelet count \> 100,000/mm3 * SGOT \< 2x ULN * Calculated creatinine clearance \> 50ml/min

Exclusion criteria

* Evidence of metastatic (stage IV) cancer on physical exam or any diagnostic study. * Pregnant or breast-feeding women * Inflammatory breast cancer * HER2 positive disease * History of hypersensitivity to a 5-FU or known dihydropyrimidine dehydrogenase (DPD) deficiency * Uncontrolled intercurrent illness * Prior history of breast cancer are ineligible except: diagnosed at least 2 years ago; present cancer is not in previously irradiated breast; no prior chemotherapy in the past 5 years; no prior high-dose chemotherapy with stem cell or bone marrow transplant. * Excisional biopsy performed prior to enrollment * Uncontrolled coagulopathy * Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome.

Design outcomes

Primary

Measure	Time frame
To determine the response rate following four cycles of preoperative capecitabine in women with operable breast cancer.	3 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026